QSC303299

QSC303299 is an undisclosed investigational drug candidate developed by the Swedish biopharmaceutical company Vicore Pharma. In early 2026, Vicore Pharma initiated a Phase I clinical trial in the United Kingdom (using the Quotient Sciences study code QSC303299) to evaluate the safety, tolerability, and pharmacokinetics of the drug in healthy male volunteers. Because the sponsor deferred the publication of the full protocol details to protect intellectual property, specific information regarding the drug's chemical structure, exact mechanism of action, and target indications remains undisclosed. However, Vicore Pharma's pipeline primarily focuses on small molecule angiotensin II type 2 receptor agonists (ATRAGs) for respiratory and fibrotic diseases.